ChAdOx1 Vaccine Dose-Sparing Strategies in Post COVID-19 patients: A Randomized Controlled Trial

Phase 2

• Conditions: Participants who recovered from COVID-19; COVID-19 Vaccine; SARS-CoV-2; Antibody; Cellular immunity; Post COVID-19; intramuscular; intradermal

• Registration Number: TCTR20211004005
• Lead Sponsor: ational Research Council of Thailand (NRCT)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-10-04
• Study Completion: 2022-11-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 360

Inclusion Criteria

1. Age 18 years or more
2. Recovered from COVID-19 for at least 3 months
3. Eligible for AstraZeneca Vaccination
4. Informed consent for participation

Exclusion Criteria

History of allergy to a component of ChAdOx1/AZD1222 (AstraZeneca)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
SARS-CoV-2 antibodies Before vaccination, 4 weeks post vaccination IgG (ELISA), Neutralizing antibody (NeutraLISA)

Secondary Outcome Measures

Name	Time	Method
Cellular immunity Before vaccination, 4 weeks post vaccination T cell (Fluorospot), Memory B cell (Fluorospot),COVID-19 infection rate 1 day post vaccination, 7 days post vaccination, 4 weeks post vaccination Symptom Assessment and confirmed with Real-time RT-PCR if suspected,Adverse events On vaccination day, 1 day post vaccination, 7 days post vaccination, 4 weeks post vaccination Patient report outcomes